All In MedTech

Device Trial Radar · NCT07043036

Randomized Controlled Trial Comparing Remote Patient Monitoring vs Standard Care in IBD Patients Initiating or Changing Advanced Therapy

Randomized Controlled Trial Comparing a Strategy Based on Continuous Monitoring at Home Using a Digital Remote Patient Monitoring Solution to Reference Standard in Patients With IBD Initiating an Advanced Therapy or Undergoing a Substantial Change in Their Advanced Therapy.

Last checked: Nov 20, 2026Latest source record: Jun 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

116

Planned (sponsor's estimate)

Start

Jun 2025

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
ResilienceNot on our public-company list
Sponsor type
Industry
Collaborators
Sanoia
First posted
Jun 29, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial aims to evaluate whether GutyCare, a digital remote patient monitoring (RPM) solution, can enhance organizational outcomes while maintaining non-inferior clinical results in patients with inflammatory bowel disease (IBD) who are initiating or undergoing significant modifications in advanced therapy. The study compares standard care to an intervention involving the use of GutyCare, a mobile application that collects patient-reported outcomes related to symptoms. When clinically significant symptoms are identified, alerts are transmitted to the care team, facilitating timely and personalized therapeutic adjustments.

Conditions

  • IBD

Interventions

  • GutyCareDevice

    Device : GutyCare The participants will use GutyCare remote patient monitoring.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of on-site IBD-related visitsTime frame: 12 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.